Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences (NYSE: EW) will announce its operating results for Q1 2022 after market close on April 26, 2022. A conference call to discuss these results is scheduled for 5:00 p.m. ET on the same day. Edwards Lifesciences is recognized for its innovations in structural heart disease and critical care monitoring. Investors can participate by dialing (877) 704-2848 or (201) 389-0893, and the call will also be streamed live on the company’s Investor Relations webpage.

Edwards Lifesciences (NYSE: EW) has received FDA approval for the MITRIS RESILIA valve, a tissue valve designed for mitral valve replacement. This innovation features a saddle-shaped sewing cuff and a low-profile frame to minimize obstruction, facilitating future transcatheter interventions. The RESILIA tissue used in the valve has undergone extensive clinical trials, demonstrating its integrity and longevity potential. The valve is already approved in Japan, Canada, and other regions, expanding Edwards' portfolio of surgical heart valve products.

Edwards Lifesciences (NYSE: EW) reported a 19% increase in sales for 2021, totaling $5.2 billion, with Q4 sales reaching $1.33 billion, up 12%. TAVR sales hit $872 million in Q4, also up 12%. The company completed pivotal trials and received FDA approval for new products. The adjusted EPS for 2021 was $2.22, a 19% rise year-over-year. For 2022, the company expects sales between $5.5 to $6 billion and adjusted EPS of $2.50 to $2.65. Edwards anticipates significant growth in transcatheter therapies, predicting a global TAVR market expansion to $10 billion by 2028.

Edwards Lifesciences (NYSE: EW) will announce its operating results for the quarter ended December 31, 2021, after market close on January 26, 2022. The company will host a conference call at 5:00 p.m. ET that same day to discuss these results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website.

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will participate in the J.P. Morgan Healthcare Conference on January 10, 2022. CEO Michael A. Mussallem is set to present virtually at 11:15 a.m. ET. A live webcast will be available on the company's investor relations website, along with an archived version later that day. Edwards Lifesciences is known for its innovations in structural heart disease and critical care monitoring.

Edwards Lifesciences has received FDA approval for the SAPIEN 3 transcatheter valve with Alterra adaptive prestent, enhancing treatment options for patients with severe pulmonary regurgitation. This innovative system combines the SAPIEN 3 valve and Alterra prestent to cater to variations in right ventricular outflow tract morphology, improving patient outcomes and reducing the need for multiple surgeries. The approval targets pediatric and adult patients requiring surgical valve replacement and is expected to significantly enhance quality of life.

Edwards Lifesciences hosted its annual investor conference, reaffirming its 2021 financial guidance and presenting a robust growth strategy for 2022. The company projects global sales of $5.5 - $6.0 billion, with TAVR sales expected to be $3.7 - $4.0 billion, reflecting a 12-15% growth. Edwards aims for substantial long-term expansion, targeting a global market opportunity of nearly $20 billion by 2028 across four product groups. With a focus on innovation and R&D, 17-18% of sales are allocated to research, underpinning confidence in double-digit growth ahead.

Edwards Lifesciences (NYSE: EW) announced promising results from the TRISCEND study, focusing on the EVOQUE transcatheter tricuspid valve replacement system. The six-month follow-up of 56 patients showed a significant reduction in tricuspid regurgitation (TR), with 100% achieving none/trace or mild TR. Other outcomes included 89% of patients in NYHA Class I or II and a survival rate of 96%. These findings were presented at the 33rd Transcatheter Cardiovascular Therapeutics conference, highlighting the potential of the EVOQUE system in treating high-risk patients.

Edwards Lifesciences (NYSE: EW) announced a cost-effectiveness analysis from the PARTNER 3 trial, revealing that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve is an economically dominant treatment compared to traditional surgery. The analysis, presented at the 33rd TCT symposium, indicated that TAVR could save over $2,000 per patient due to reduced hospital stays and follow-up costs, while improving quality-adjusted life expectancy. With a 95% probability of being highly cost-effective, this finding empowers both patients and cardiologists in treatment decisions.